Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition.
暂无分享,去创建一个
R. Rodenburg | B. V. van Engelen | J. Smeitink | J. Beyrath | N. Voermans | F. Russel | P. Willems | W. Koopman | T. Schirris | U. Brandt | G. Renkema | T. Ritschel | A. Bilos | Baziel G.M. van Engelen
[1] M. Medina,et al. GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals. , 2015, Cell metabolism.
[2] R. Rodenburg,et al. SDHA mutations causing a multisystem mitochondrial disease: novel mutations and genetic overlap with hereditary tumors , 2014, European Journal of Human Genetics.
[3] K. Reue,et al. Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. , 2014, Cell Metabolism.
[4] D. Barrett,et al. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. , 2014, Translational research : the journal of laboratory and clinical medicine.
[5] D. Voora,et al. Phenotype Standardization for Statin-Induced Myotoxicity , 2014, Clinical pharmacology and therapeutics.
[6] W. Tong,et al. Drug-induced rhabdomyolysis: from systems pharmacology analysis to biochemical flux. , 2014, Chemical research in toxicology.
[7] F. Mastaglia,et al. Statin myotoxicity: A review of genetic susceptibility factors , 2014, Neuromuscular Disorders.
[8] B. Psaty,et al. GATM gene variants and statin myopathy risk , 2014, Nature.
[9] P. Thompson,et al. Does reduced creatine synthesis protect against statin myopathy? , 2013, Cell metabolism.
[10] Christopher D. Brown,et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy , 2013, Nature.
[11] A. Åsberg,et al. UGT1A1*28 is Associated with Decreased Systemic Exposure of Atorvastatin Lactone , 2013, Molecular Diagnosis & Therapy.
[12] Lucía Pronsato,et al. High passage numbers induce resistance to apoptosis in C2C12 muscle cells. , 2013, Biocell : official journal of the Sociedades Latinoamericanas de Microscopia Electronica ... et. al.
[13] P. Thompson,et al. Effect of Statins on Skeletal Muscle Function , 2012, Circulation.
[14] J. DiNicolantonio. CoQ10 and L-carnitine for statin myalgia? , 2012, Expert review of cardiovascular therapy.
[15] Beatrice A. Golomb,et al. A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class , 2012, PloS one.
[16] Tina Ritschel,et al. Pharmacophore Fingerprint-Based Approach to Binding Site Subpocket Similarity and Its Application to Bioisostere Replacement , 2012, J. Chem. Inf. Model..
[17] P. Sirvent,et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. , 2012, Toxicology and applied pharmacology.
[18] S. Krähenbühl,et al. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. , 2011, Biochimica et biophysica acta.
[19] T. A. Jacobson,et al. Statin-induced myopathy: a review and update , 2011, Expert opinion on drug safety.
[20] C. Angelini,et al. EFNS guidelines on the diagnostic approach to pauci‐ or asymptomatic hyperCKemia , 2010, European journal of neurology.
[21] R. Rodenburg. Biochemical diagnosis of mitochondrial disorders , 2010, Journal of Inherited Metabolic Disease.
[22] S. Krähenbühl,et al. Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. , 2010, Biochemical pharmacology.
[23] E. Gnaiger. Capacity of oxidative phosphorylation in human skeletal muscle: new perspectives of mitochondrial physiology. , 2009, The international journal of biochemistry & cell biology.
[24] F. Daldal,et al. The role of molecular modeling in the design of analogues of the fungicidal natural products crocacins A and D. , 2008, Bioorganic & medicinal chemistry.
[25] R. Houtkooper,et al. Mutations in LPIN1 cause recurrent acute myoglobinuria in childhood. , 2008, American journal of human genetics.
[26] R. Collins,et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.
[27] P. Sirvent,et al. New insights into mechanisms of statin-associated myotoxicity. , 2008, Current opinion in pharmacology.
[28] R. Margreiter,et al. Analysis of mitochondrial function in situ in permeabilized muscle fibers, tissues and cells , 2008, Nature Protocols.
[29] A. Åsberg,et al. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[30] J. Smeitink,et al. Life cell quantification of mitochondrial membrane potential at the single organelle level , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[31] Michiaki Yamashita,et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. , 2007, The Journal of clinical investigation.
[32] J. Armitage,et al. The safety of statins in clinical practice , 2007, The Lancet.
[33] P. Thompson,et al. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. , 2007, Journal of the American College of Cardiology.
[34] R. Rodenburg,et al. Spectrophotometric assay for complex I of the respiratory chain in tissue samples and cultured fibroblasts. , 2007, Clinical chemistry.
[35] Anne E Carpenter,et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes , 2006, Genome Biology.
[36] Zachary Simmons,et al. Genetic risk factors associated with lipid‐lowering drug‐induced myopathies , 2006, Muscle & nerve.
[37] R. Rodenburg,et al. Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology. , 2006, Clinical chemistry.
[38] A. Arduini,et al. Improvement of statin‐associated myotoxicity by L‐carnitine , 2004, Journal of thrombosis and haemostasis : JTH.
[39] A. Sánchez Navarro,et al. Clinical pharmacokinetics of statins. , 2003, Methods and findings in experimental and clinical pharmacology.
[40] C. M. White. A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin , 2002, Journal of clinical pharmacology.
[41] B. Ma,et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[42] Bertram Pitt,et al. Withdrawal of cerivastatin from the world market , 2001, Current controlled trials in cardiovascular medicine.
[43] J. Deisenhofer,et al. Structural Mechanism for Statin Inhibition of HMG-CoA Reductase , 2001, Science.
[44] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[45] F. Gabreëls,et al. Clinical heterogeneity in respiratory chain complex III deficiency in childhood , 1997, Journal of the Neurological Sciences.
[46] B. Trumpower,et al. The protonmotive Q cycle in mitochondria and bacteria. , 1994, Critical reviews in biochemistry and molecular biology.
[47] H. Schägger,et al. Characterisation of binding of the methoxyacrylate inhibitors to mitochondrial cytochrome c reductase. , 1988, European journal of biochemistry.